IAXO-102 (CD14/TLR4 Antagonist) (synthetic) [1115270-63-7]

Catalog number: IAX-600-002-M001
Brand: Innaxon
Packing: 1 mg
Other sizes: Other size available
Price: € 250.00
Expected delivery time: 7 days
Quantity:
Chemical Structure
Chemical Structure...

Product specifications for - IAXO-102 (CD14/TLR4 Antagonist) (synthetic) [1115270-63-7]

Overview: 
Product group: Chemicals
Category: Inhibitors / activators
CAS No.: 1115270-63-7
Properties: 
Purity: >98%
Molecular Formula: C35H71NO5
Molecular weight: 585.94g/mol
Datasheet: Datasheet
  Research Use Only
UNSPSC: 51202000
Storage instructions: 2-¦C to 8-¦C
Scientific information: 
Scientific info: CD14/TLR4 antagonist. Inhibitor of sterile inflammation. Synthetic TLR4/CD14 ligand with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. Useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. Shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation, and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. Useful tool, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4s key role in the defense of pathogens. - Chemical. CAS: 1115270-63-7. Formula: C35H71NO5. MW: 585.94g/mol. Synthetic. CD14/TLR4 antagonist. Inhibitor of sterile inflammation. Synthetic TLR4/CD14 ligand with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. Useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. Shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation, and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. Useful tool, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4s key role in the defense of pathogens.
Safety information: 
MSDS: MSDS
Hazard information: Non-hazardous
Additional information: 
Synonyms: IAX-600-002-M001
Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides: F. Peri, et al.; Angew. Chem.46, 3308 (2007) Read more
TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice: I. Bettoni, et al.; Glia 56, 1312 (2008) Read more
Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization: M. Piazza, et al.; J. Med. Chem. 52, 1209 (2009) Read more
Evidence of a specific interaction between new synthetic antisepsis agents and CD14: M. Piazza, et al.; Biochemistry 48, 12337 (2009) Read more
Exploring the LPS/TLR4 signal pathway with small molecules: F. Peri, et al.; Biochem. Soc. Trans. 38, 1390 (2010) (Review) Read more
Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists: F. Peri & M. Piazza; Biotechnol. Adv. 30, 251 (2012) (Review) Read more
Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics: F. Peri, et al.; Pure Appl. Chem. 84, 97 (2012) (Review) Read more
Toll like receptor 4 antagonist prevents acetaminophen induced acute liver failure in mice: a novel therapeutic strategy: N. Shah, et al.; Gut 61, A28 (2012) Read more
Multivalent glycoconjugates as anti-pathogenic agents. A. Bernardi, et al.; Chem. Soc. Rev. 42, 4709 (2013) (Review) Read more
Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update: F. Peri & V. Calabrese; Med. Chem. 57, 3612 (2014) (Review) Read more